Researchers at the Hadassah Medical Organization have introduced a new blood test that offers early detection of potentially fatal lung damage in cancer patients taking antibody-drug conjugates (ADCs).
Led by Dr. Albert Grinshpun from the Sharett Institute of Oncology and Dr. Ori Fridlich from the Center for Liquid Biopsy at the Department of Pediatric Hemato-Oncology, the team’s groundbreaking findings could lead to a safer and simpler way to monitor patients taking powerful cancer drugs, thereby possibly reducing the need for frequent scans.
Read the full story on AlphaGalileo, a source for breaking research news for journalists around the world.
Read More
